As part of our series of white papers tracking clinical trial activity across the world, GlobalData recently compiled a summary of global clinical trials in monoclonal antibodies (mAbs). GlobalData identified 5,273 industry clinical trials with a start date between January 1, 2007, and December 31, 2016.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

GlobalData analysed the dataset to identify the top drugs investigated in industry-sponsored clinical trials in mAbs. The top three drugs were bevacizumab, adalimumab, and tocilizumab. These were followed by rituximab, nivolumab, pembrolizumab, ranibizumab, secukinumab, trastuzumab, and ipilimumab. All the top ten drugs are marketed and the majority of the trials initiated for these drugs were Phase III trials, closely followed by Phase IV and Phase II, as shown in Figure 1. However, the largest share of bevacizumab trials were in Phase II, with 35% of trials occurring in indications for which the drug has not yet been approved.